Cargando…
Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study
BACKGROUND: Liposomal bupivacaine (LB) is a long-acting formulation of bupivacaine. The safety and efficacy of LB has been demonstrated across surgical procedures. However, pharmacokinetic (PK) parameters and safety of LB in the Chinese population have not been assessed. METHODS: In this single-arm,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314475/ https://www.ncbi.nlm.nih.gov/pubmed/34315419 http://dx.doi.org/10.1186/s12871-021-01407-5 |
_version_ | 1783729560534122496 |
---|---|
author | Cheung, Bernard MY Ng, Pauline Yeung Liu, Ying Zhou, Manman Yu, Vincent Yang, Julia Wang, Natalie Q. |
author_facet | Cheung, Bernard MY Ng, Pauline Yeung Liu, Ying Zhou, Manman Yu, Vincent Yang, Julia Wang, Natalie Q. |
author_sort | Cheung, Bernard MY |
collection | PubMed |
description | BACKGROUND: Liposomal bupivacaine (LB) is a long-acting formulation of bupivacaine. The safety and efficacy of LB has been demonstrated across surgical procedures. However, pharmacokinetic (PK) parameters and safety of LB in the Chinese population have not been assessed. METHODS: In this single-arm, single center, phase 1, open-label study, PK and safety of local infiltration with LB 266 mg were assessed in healthy Chinese adults. Eligible participants were aged 18 to 55 years with biologic parents and grandparents of Chinese ethnicity, in generally good health (i.e., no clinically significant abnormalities), and with a body mass index (BMI) 19.0 to 24.0 kg/m(2) (inclusive) and body weight ≥ 50 kg. RESULTS: Participants (N = 20) were predominantly men (80 %); mean age was 32 years; and mean BMI was 21.8 kg/m(2). After LB administration, mean plasma levels of bupivacaine rapidly increased during the first hour and continued to increase through 24 h; plasma levels then gradually decreased through 108 h followed by a monoexponential decrease through 312 h. Geometric mean maximum plasma concentration was 170.9 ng/mL; the highest plasma bupivacaine concentration detected in any participant was 374.0 ng/mL. Twenty-two treatment-emergent adverse events were reported (mild, n = 21; moderate, n = 1). CONCLUSIONS: After single-dose administration of LB, PK measures were similar to a previously reported profile in US adults. The highest observed peak plasma concentration of bupivacaine was several-fold below the plasma concentration threshold accepted as being associated with neurotoxicity or cardiotoxicity (2000–4000 ng/mL). These data support that LB is well tolerated and safe in individuals of Chinese descent. TRIAL REGISTRATION: NCT04158102 (ClinicalTrials.gov identifier), Date of registration: November 5, 2019. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12871-021-01407-5. |
format | Online Article Text |
id | pubmed-8314475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83144752021-07-28 Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study Cheung, Bernard MY Ng, Pauline Yeung Liu, Ying Zhou, Manman Yu, Vincent Yang, Julia Wang, Natalie Q. BMC Anesthesiol Research BACKGROUND: Liposomal bupivacaine (LB) is a long-acting formulation of bupivacaine. The safety and efficacy of LB has been demonstrated across surgical procedures. However, pharmacokinetic (PK) parameters and safety of LB in the Chinese population have not been assessed. METHODS: In this single-arm, single center, phase 1, open-label study, PK and safety of local infiltration with LB 266 mg were assessed in healthy Chinese adults. Eligible participants were aged 18 to 55 years with biologic parents and grandparents of Chinese ethnicity, in generally good health (i.e., no clinically significant abnormalities), and with a body mass index (BMI) 19.0 to 24.0 kg/m(2) (inclusive) and body weight ≥ 50 kg. RESULTS: Participants (N = 20) were predominantly men (80 %); mean age was 32 years; and mean BMI was 21.8 kg/m(2). After LB administration, mean plasma levels of bupivacaine rapidly increased during the first hour and continued to increase through 24 h; plasma levels then gradually decreased through 108 h followed by a monoexponential decrease through 312 h. Geometric mean maximum plasma concentration was 170.9 ng/mL; the highest plasma bupivacaine concentration detected in any participant was 374.0 ng/mL. Twenty-two treatment-emergent adverse events were reported (mild, n = 21; moderate, n = 1). CONCLUSIONS: After single-dose administration of LB, PK measures were similar to a previously reported profile in US adults. The highest observed peak plasma concentration of bupivacaine was several-fold below the plasma concentration threshold accepted as being associated with neurotoxicity or cardiotoxicity (2000–4000 ng/mL). These data support that LB is well tolerated and safe in individuals of Chinese descent. TRIAL REGISTRATION: NCT04158102 (ClinicalTrials.gov identifier), Date of registration: November 5, 2019. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12871-021-01407-5. BioMed Central 2021-07-27 /pmc/articles/PMC8314475/ /pubmed/34315419 http://dx.doi.org/10.1186/s12871-021-01407-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cheung, Bernard MY Ng, Pauline Yeung Liu, Ying Zhou, Manman Yu, Vincent Yang, Julia Wang, Natalie Q. Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study |
title | Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study |
title_full | Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study |
title_fullStr | Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study |
title_full_unstemmed | Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study |
title_short | Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study |
title_sort | pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy chinese adults: a phase 1 study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314475/ https://www.ncbi.nlm.nih.gov/pubmed/34315419 http://dx.doi.org/10.1186/s12871-021-01407-5 |
work_keys_str_mv | AT cheungbernardmy pharmacokineticsandsafetyofliposomalbupivacaineafterlocalinfiltrationinhealthychineseadultsaphase1study AT ngpaulineyeung pharmacokineticsandsafetyofliposomalbupivacaineafterlocalinfiltrationinhealthychineseadultsaphase1study AT liuying pharmacokineticsandsafetyofliposomalbupivacaineafterlocalinfiltrationinhealthychineseadultsaphase1study AT zhoumanman pharmacokineticsandsafetyofliposomalbupivacaineafterlocalinfiltrationinhealthychineseadultsaphase1study AT yuvincent pharmacokineticsandsafetyofliposomalbupivacaineafterlocalinfiltrationinhealthychineseadultsaphase1study AT yangjulia pharmacokineticsandsafetyofliposomalbupivacaineafterlocalinfiltrationinhealthychineseadultsaphase1study AT wangnatalieq pharmacokineticsandsafetyofliposomalbupivacaineafterlocalinfiltrationinhealthychineseadultsaphase1study |